ArticleJournal of cardiothoracic surgery2025
Venous external support enhanced coronary artery bypass grafting: a multicentric cohort experience.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vein Graft Preservation During Coronary Artery Bypass Graft Surgery: Operative Techniques, Biomaterials and Advances from Tissue Engineering.Journal of functional biomaterials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis multicentric study evaluated short- and mid-term clinical outcomes, with specific focus on the need for repeat revascularization, in patients undergoing coronary artery bypass grafting (CABG) with VEST supported saphenous vein graft (SVG).
methodsA total of 397 patients underwent CABG in a three-center setting, with or without concomitant procedures, with at least one SVG supported with an external stent. Open vein harvesting was performed in 80.3% of patients. The majority (73.3%) of patients underwent on-pump CABG, 6.8% of patients had concomitant valve surgery, and the average number of grafts per patient was three. Patients were followed for major adverse cardiac and cerebral events (MACCE) for a median duration of 24 (1-101) months.
resultsOverall, 469 of 654 SVG (71.7%) received external stents. Freedom from MACCE at 1, 3, and 5 years was 95.1% (SE 0.011), 85.4% (SE 0.021), and 82.4% (SE 0.030) respectively. Revascularization rates in territories which were grafted with a stented SV was low in general (1.28%) and statistically significantly lower than in territories grafted with a non-stented SVG (4.32%, p = 0.015). Arterially grafted territories confirmed low revascularization rates as well (0.9%).
conclusionsVEST-enhanced CABG is feasible and associated with low MACCE in real world routine practice which includes on and off pump CABG, sequential grafting, and concomitant surgery. Short- to mid-term clinical follow up suggests that VEST enhanced CABG is associated with very low target vessel revascularization rates, with most re-revascularization happening at non-grafted or non-VEST-enhanced grafted territories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.